{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:59:29Z","timestamp":1790521169722,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2021,4,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell\u2013like (ABC) subtype. Eastern Cooperative Oncology Group (ECOG)-ACRIN trial E1412 was a randomized phase II study comparing R2CHOP versus R-CHOP in untreated DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>Patients with newly diagnosed DLBCL, stage II bulky-IV disease, International Prognostic Index (IPI) \u2265 2, and ECOG performance status \u2264 2 were eligible and randomly assigned 1:1 to R2CHOP versus R-CHOP for six cycles. Tumors were analyzed using the NanoString Lymph2Cx for cell of origin. The primary end point was progression-free survival (PFS) in all patients with the co-primary end point of PFS in ABC-DLBCL. Secondary end points included overall response rate (ORR), complete response (CR) rate, and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Three hundred forty-nine patients were enrolled; 280 patients (145 R2CHOP and 135 R-CHOP) were evaluable: 94 were ABC-DLBCL, 122 germinal center B-cell\u2013like-DLBCL, 18 unclassifiable, and 46 unknowns. Baseline characteristics were well-balanced between arms, and the median age was 66 (range, 24-92); 70% of patients had stage IV disease; 34%, 43%, and 24% had IPI 2, 3, and 4 or 5, respectively. Myelosuppression was more common in the R2CHOP arm. The ORR and CR rate were 92% and 68% in R-CHOP and 97% ( P = .06) and 73% ( P = .43) in the R2CHOP arm, respectively. The median follow-up was 3.0 years; R2CHOP was associated with a 34% reduction in risk of progression or death versus R-CHOP (hazard ratio [HR], 0.66 95% CI, 0.43 to 1.01) and 3-year PFS of 73% versus 61%, one-sided P = .03, and an improvement in OS (83% and 75% at 3 years; HR, 0.67; one-sided P = .05). The PFS HR for R2CHOP was 0.67 for ABC-DLBCL, one-sided P = .1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>In this signal-seeking study, the addition of lenalidomide to R-CHOP (R2CHOP) improved outcomes in newly diagnosed DLBCL including patients with ABC-DLBCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.20.01375","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T16:36:49Z","timestamp":1612802209000},"page":"1329-1338","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":103,"title":["Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412"],"prefix":"10.1200","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz S.","family":"Nowakowski","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8049-0086","authenticated-orcid":false,"given":"Fangxin","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Center for Lymphoid Cancer, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Macon","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7132-0226","authenticated-orcid":false,"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[{"name":"University of Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3802-3860","authenticated-orcid":false,"given":"James L.","family":"Wade","sequence":"additional","affiliation":[{"name":"Heartland NORP, Decatur IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri G.","family":"Nagargoje","sequence":"additional","affiliation":[{"name":"Marcy Hospital, Coon Rapids, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Saint Joseph Mercy Hospital, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Emory University-Winship Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-4129","authenticated-orcid":false,"given":"Nadia","family":"Khan","sequence":"additional","affiliation":[{"name":"Fox Case Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4117-2469","authenticated-orcid":false,"given":"Jennifer E.","family":"Amengual","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy L.","family":"Richards","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, NY"},{"name":"Deceased."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-1699","authenticated-orcid":false,"given":"R. F.","family":"Little","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"University of Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-8161","authenticated-orcid":false,"given":"Lale","family":"Kostakoglu","sequence":"additional","affiliation":[{"name":"University of Virginia, Charlottesville VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14813"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw257"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2818"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5714"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70191-3"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.2174\/1568009616666160408145741"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16300"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.165"},{"key":"b13","volume-title":"World Health Organization Classification of Tumours","author":"Swerdlow SH","year":"2008"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0064-9"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5198"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536433"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1002\/hon.5_2629"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220475"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0097-4"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445"},{"key":"b23","author":"Hartert KT","journal-title":"Leukemia"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.20.01375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T05:52:26Z","timestamp":1653803546000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.20.01375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,4,20]]}},"alternative-id":["10.1200\/JCO.20.01375"],"URL":"https:\/\/doi.org\/10.1200\/jco.20.01375","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"2020-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}